William Davis, MD
Cardiovascular Disease · Auburn, ALNPI 1790716165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in AL, where the typical reported total is $2,733.
Across 72 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$180
- Amgen$171
- Lexicon Pharmaceuticals, Inc.$145
- Idorsia Pharmaceuticals US Inc$122
- Actelion Pharmaceuticals US, Inc.$122
- Zimmer Biomet$113
- plus $677 from 19 others
Across 55 payments — averaging $30,576 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$1.5M
- Amgen$60K
- Regeneron$36K
- Boehringer Ingelheim Pharma GmbH & Co.kg$36K
- Boehringer Ingelheim International GmbH$16K
- Pfizer$11K
- plus $17K from 3 others
What the payments were for
- Travel & lodging$1228%
- Food & beverage$1,40492%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $180 |
| Amgen | 12 | $171 |
| Lexicon Pharmaceuticals, Inc. | 7 | $145 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| Actelion Pharmaceuticals US, Inc. | 6 | $122 |
| Zimmer Biomet | 1 | $113 |
| Esperion Therapeutics, Inc. | 5 | $112 |
| Novo Nordisk | 2 | $99 |
| Heartflow, Inc. | 2 | $51 |
| Bayer | 2 | $46 |
| United Therapeutics Corporation | 3 | $44 |
| Boehringer Ingelheim | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Merck | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Medicomp Inc | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Medtronic | 1 | $16 |
| Elutia, Inc. | 2 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,528 in reported general payments places this provider in the 35th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 218 | $220,235 |
| EliquisApixaban | 228 | $212,647 |
| Repatha SureclickEvolocumab | 140 | $104,743 |
| VerquvoVericiguat | 85 | $92,086 |
| XareltoRivaroxaban | 39 | $51,458 |
| Ambrisentan | 13 | $18,439 |
| FarxigaDapagliflozin Propanediol | 16 | $11,929 |
| Propafenone Hcl ErPropafenone Hcl | 20 | $11,782 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $11,141 |
| LivaloPitavastatin Calcium | 16 | $10,555 |
| BrilintaTicagrelor | 17 | $10,273 |
| Praluent PenAlirocumab | 19 | $9,356 |
| Tadalafil | 19 | $7,713 |
| Ranolazine ErRanolazine | 40 | $7,473 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $7,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $180 | $220,235218 claims |
| MerckVerquvo | $31 | $92,08685 claims |
| AstraZenecaFarxiga, Brilinta | $30 | $22,20233 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $112 | $15,51823 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $28 | $10,55516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Auburn
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Ajit NaiduFlorence$66K
- Mahomed SalameAnniston$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.